Klaria AB specializes in the development of innovative drug delivery systems, focusing on enhancing the efficacy and safety of medications. The company employs a proprietary technology platform that utilizes microneedle arrays for transdermal drug delivery. This method allows for the painless administration of therapeutics, bypassing the gastrointestinal tract and first-pass metabolism, which can often reduce drug effectiveness. Klaria's approach aims to improve patient compliance and provide a more controlled release of active pharmaceutical ingredients.

In addition to microneedle technology, Klaria AB is also engaged in the formulation of various drug compounds to optimize their delivery and therapeutic outcomes. The company emphasizes the importance of scientific research and development in its processes, ensuring that their products are backed by robust clinical data. By leveraging advanced materials and innovative delivery mechanisms, Klaria aims to address unmet medical needs and enhance the overall patient experience in medication administration.

Sweden

Klaria AB is a pharmaceutical company developing innovative pharmaceuticals for migraine, cancer-related pain and opioid overdoses.

Klaria AB

Company Details